Royal College of Surgeons in Ireland
Browse
PARP Inhibitors in Breast Cancer.....pdf (1000.5 kB)

PARP inhibitors in breast cancer: a short communication

Download (1000.5 kB)
journal contribution
posted on 2024-02-09, 10:38 authored by Gordon DalyGordon Daly, Maen Monketh AlRawashdeh, Jason McGrathJason McGrath, Gavin DowlingGavin Dowling, Luke Cox, Sindhuja Naidoo, Damir VareslijaDamir Vareslija, Arnold HillArnold Hill, Leonie YoungLeonie Young

Purpose of review: In the last decade, poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in the treatment of several cancers, such as breast and ovarian cancer. This article aims to discuss the current uses, limitations, and future directions for PARP inhibitors (PARPis) in the treatment of breast cancer.

Recent findings: Following the results of the OlympiAD and EMBRACA trials, PARPis were approved in HER2-negative breast cancer with a germline BRCA mutation. We reviewed this class of drugs' mechanism of action, efficacy, and limitations, as well as further studies that discussed resistance, impaired homologous recombination repair (HRR), and the combination of PARPis with other drugs. Improving understanding of HRR, increasing the ability to target resistance, and combining PARPis with other novel agents are continuing to increase the clinical utility of PARPis.

Funding

Open Access funding provided by the IReL Consortium

History

Comments

The original article is available at https://link.springer.com/

Published Citation

Daly GR. et al. PARP inhibitors in breast cancer: a short communication. Curr Oncol Rep. 2024

Publication Date

2 January 2024

PubMed ID

38236558

Department/Unit

  • Beaumont Hospital
  • Surgery

Research Area

  • Cancer

Publisher

Springer

Version

  • Published Version (Version of Record)